Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680354 | 0.87 | LMNA (0.62) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL21645618 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL30272141 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL17844954 | 0.80 | LMNA (1.00) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL5138522 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL2017838 | 0.80 | LMNA (0.67) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL18153335 | 0.78 | LMNA (0.59) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL10615652 | 0.76 | MAPT (1.00) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL25873158 | 0.76 | LMNA (0.47) | LMNAMAPTALDH1A1HTTPKM | |
| SCHEMBL25873138 | 0.76 | LMNA (0.47) | LMNAMAPTALDH1A1HTTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059802-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | Bipar Sciences, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | claimed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-20240366568-A1 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | UNIV CASE WESTERN RESERVE (US) | 2024-11-07 | — | — | US | disclosed |
| CN-118496217-A | Inhibitors of alpha-amino-beta-carboxyhexadienoic acid semialdehyde decarboxylase | TES制药有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| US-11931339-B2 | Compositions and methods for treating tissue injury | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3419632-B1 | NR OR NMN FOR ENHANCING LIVER REGENERATION | UNIV PENNSYLVANIA (US) | 2023-12-20 | — | — | EP | disclosed |
| US-11559522-B2 | Methods for enhancing liver regeneration | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210346365-A1 | METHODS FOR ENHANCING LIVER REGENERATION | THE TRUSTEES OF THE UNIVERSTIY OF PENNSYLVANIA (US) | 2021-11-11 | — | — | US | disclosed |
| CN-113302189-A | Inhibitors of alpha-amino-beta-carboxyadipimic acid semialdehyde decarboxylating enzyme | TES制药有限责任公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-113121450-A | Alpha-amino-beta-carboxymuconate semialdehyde decarboxylase inhibitors | TES制药有限责任公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| WO-2008030887-A2 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-6004978-A | ADMINISTERING AS ANTITUMOR AGENT OR VIRICIDE | OCTAMER, INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0698019-B1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER INC (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5670518-A | ANTITUMOR AGENTS; VIRICIDES | OCTAMER, INC. | 1997-09-23 | — | — | US | disclosed |
| US-5652367-A | ANTICANCER AGENTS | OCTAMER, INC. | 1997-07-29 | — | — | US | disclosed |
| EP-0698019-A1 | NOVEL AROMATIC NITRO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1996-02-28 | — | — | EP | disclosed |
| US-5464871-A | Aromatic amides | OCTAMER, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1994026730-A2 | NOVEL AROMATIC NITRO AND NITROSO COMPOUNDS AND THEIR METABOLITES USEFUL AS ANTI-VIRAL AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076778-A1 | METHODS FOR DESIGNING PARP INHIBITORS AND USES THEREOF | PARP3, PARP1, PARP15 | LMNA 554/4885MAPT 3488/4885ALDH1A1 1787/4885 |
| US-11931339-B2 | Compositions and methods for treating tissue injury | PDK4, AK1, PDK1 | LMNA 1588/4885MAPT 2286/4885ALDH1A1 123/4885 |
| US-20210346365-A1 | METHODS FOR ENHANCING LIVER REGENERATION | NNT, SIRT1, NADK | LMNA 1502/4885MAPT 4358/4885ALDH1A1 257/4885 |
| US-11559522-B2 | Methods for enhancing liver regeneration | NNT, SIRT1, NADK | LMNA 1502/4885MAPT 4358/4885ALDH1A1 257/4885 |
| US-20240366568-A1 | COMPOSITIONS AND METHODS FOR TREATING TISSUE INJURY | PDK4, AK1, PDK1 | LMNA 1588/4885MAPT 2286/4885ALDH1A1 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.